乳腺癌新辅助化疗疗效评价。
Evaluation of the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer.
机构信息
Department of Breast Surgery, The First Affiliated Hospital of China Medical University, Shenyang City, Liaoning Province, People's Republic of China.
出版信息
Drug Des Devel Ther. 2020 Jun 18;14:2423-2433. doi: 10.2147/DDDT.S253961. eCollection 2020.
Abstract
Neoadjuvant chemotherapy is increasingly used in breast cancer, especially for downstaging the primary tumor in the breast and the metastatic axillary lymph node. Accurate evaluations of the response to neoadjuvant chemotherapy provide important information on the impact of systemic therapies on breast cancer biology, prognosis, and guidance for further therapy. Moreover, pathologic complete response is a validated and valuable surrogate prognostic factor of survival after therapy. Evaluations of neoadjuvant chemotherapy response are very important in clinical work and basic research. In this review, we will elaborate on evaluations of the efficacy of neoadjuvant chemotherapy in breast cancer and provide a clinical evaluation procedure for neoadjuvant chemotherapy.
摘要
新辅助化疗在乳腺癌中的应用越来越多，尤其是在降期原发性乳腺癌和转移性腋窝淋巴结方面。准确评估新辅助化疗的反应可提供有关全身治疗对乳腺癌生物学、预后的影响的重要信息，并为进一步治疗提供指导。此外，病理完全缓解是治疗后生存的一个经过验证且有价值的替代预后因素。评估新辅助化疗反应在临床工作和基础研究中都非常重要。在这篇综述中，我们将详细阐述乳腺癌新辅助化疗疗效的评估，并提供新辅助化疗的临床评估程序。
相似文献
1
Evaluation of the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer.乳腺癌新辅助化疗疗效评价。
Drug Des Devel Ther. 2020 Jun 18;14:2423-2433. doi: 10.2147/DDDT.S253961. eCollection 2020.
2
Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.新辅助化疗的临床和病理反应与局部晚期乳腺癌预后的关系
J Surg Oncol. 2002 May;80(1):4-11. doi: 10.1002/jso.10090.
3
Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy.新辅助化疗治疗患者术前记录的乳腺癌腋窝淋巴结转移灶根除的发生率及影响
Ann Surg. 1999 Jul;230(1):72-8. doi: 10.1097/00000658-199907000-00011.
4
Level III axillary lymph nodes involvement in node positive breast cancer received neoadjuvant chemotherapy.腋窝淋巴结转移至Ⅲ级的阳性乳腺癌患者接受了新辅助化疗。
Breast. 2013 Dec;22(6):1161-5. doi: 10.1016/j.breast.2013.08.004. Epub 2013 Sep 27.
5
6
Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer.新辅助化疗后残留的腋窝转移性淋巴结可预测局部晚期乳腺癌患者的无病生存期。
Am J Surg. 1998 Dec;176(6):502-9. doi: 10.1016/s0002-9610(98)00253-0.
7
Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.接受基于阿霉素新辅助化疗的乳腺癌患者原发性肿瘤及腋窝淋巴结完全病理缓解的临床病程
J Clin Oncol. 1999 Feb;17(2):460-9. doi: 10.1200/JCO.1999.17.2.460.
8
[Axillary pathologic response after neoadjuvant chemotherapy in locally advanced breast cancer with axillary involvement].[局部晚期伴腋窝受累乳腺癌新辅助化疗后的腋窝病理反应]
Rev Esp Med Nucl Imagen Mol. 2015 Jul-Aug;34(4):230-5. doi: 10.1016/j.remn.2015.01.005. Epub 2015 Mar 3.
9
American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome.新辅助化疗后的美国癌症联合委员会肿瘤-淋巴结-转移分期与乳腺癌预后
J Natl Cancer Inst. 2005 Aug 3;97(15):1137-42. doi: 10.1093/jnci/dji206.
引用本文的文献
1
Development and validation of an F-FDG PET/CT radiomic nomogram for predicting axillary lymph-node status after neoadjuvant chemotherapy for breast cancer: a multicenter study.用于预测乳腺癌新辅助化疗后腋窝淋巴结状态的F-FDG PET/CT影像组学列线图的开发与验证：一项多中心研究
Ann Nucl Med. 2025 Aug 17. doi: 10.1007/s12149-025-02099-4.
2
Recent Insights Into Breast Cancer: Molecular Pathways, Epigenetic Regulation, and Emerging Targeted Therapies.乳腺癌的最新见解：分子途径、表观遗传调控及新兴靶向治疗
Breast Cancer (Auckl). 2025 Jul 13;19:11782234251355663. doi: 10.1177/11782234251355663. eCollection 2025.
3
The prognostic differences between breast-conserving surgery and mastectomy in patients with invasive ductal carcinoma who achieved complete response following neoadjuvant chemotherapy: a propensity score matched analysis based on the SEER database.新辅助化疗后达到完全缓解的浸润性导管癌患者保乳手术与乳房切除术的预后差异：基于监测、流行病学与最终结果（SEER）数据库的倾向评分匹配分析
World J Surg Oncol. 2025 Jul 8;23(1):269. doi: 10.1186/s12957-025-03932-w.
4
Development and validation of an MRI spatiotemporal interaction model for early noninvasive prediction of neoadjuvant chemotherapy response in breast cancer: a multicentre study.用于乳腺癌新辅助化疗反应早期无创预测的MRI时空相互作用模型的开发与验证：一项多中心研究
EClinicalMedicine. 2025 Jun 12;85:103298. doi: 10.1016/j.eclinm.2025.103298. eCollection 2025 Jul.
5
The impact of serum interleukin-17a as a predictive biomarker for neoadjuvant therapy response in breast cancer: a retrospective study.血清白细胞介素-17a作为乳腺癌新辅助治疗反应预测生物标志物的影响：一项回顾性研究。
Gland Surg. 2025 May 30;14(5):929-937. doi: 10.21037/gs-2025-197. Epub 2025 May 27.
6
Visualization of research trend of neoadjuvant chemotherapy for breast cancer treatment: a bibliometric analysis.乳腺癌新辅助化疗治疗研究趋势的可视化分析：一项文献计量学分析
Discov Oncol. 2025 Jun 19;16(1):1154. doi: 10.1007/s12672-025-02950-0.
7
Self-reported side effects of breast cancer treatment and its impact on quality of life: a multicenter cross-sectional study in a low- and middle-income country.乳腺癌治疗的自我报告副作用及其对生活质量的影响：一项在低收入和中等收入国家开展的多中心横断面研究
BMC Cancer. 2025 Jun 1;25(1):975. doi: 10.1186/s12885-025-14381-9.
8
Personalizing Neoadjuvant Chemotherapy: The Impact of BRCA Variants on Pathologic Complete Response in Luminal B Breast Cancer.个性化新辅助化疗：BRCA 变异对 luminal B 型乳腺癌病理完全缓解的影响
Cancers (Basel). 2025 May 10;17(10):1619. doi: 10.3390/cancers17101619.
9
Machine learning prediction of pathological complete response to neoadjuvant chemotherapy with peritumoral breast tumor ultrasound radiomics: compare with intratumoral radiomics and clinicopathologic predictors.基于瘤周乳腺肿瘤超声影像组学的新辅助化疗病理完全缓解的机器学习预测：与瘤内影像组学及临床病理预测指标的比较
Breast Cancer Res Treat. 2025 May 16. doi: 10.1007/s10549-025-07727-1.
10
Targeting Triple-Negative Breast Cancer: Resistance Mechanisms and Therapeutic Advancements.靶向三阴性乳腺癌：耐药机制与治疗进展
Cancer Med. 2025 May;14(9):e70803. doi: 10.1002/cam4.70803.
本文引用的文献
1
Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis.新辅助化疗后病理完全缓解对乳腺癌复发和生存的影响：一项综合荟萃分析。
Clin Cancer Res. 2020 Jun 15;26(12):2838-2848. doi: 10.1158/1078-0432.CCR-19-3492. Epub 2020 Feb 11.
2
Breast cancer phenotype influences MRI response evaluation after neoadjuvant chemotherapy.乳腺癌表型影响新辅助化疗后 MRI 反应评估。
Eur J Radiol. 2019 Nov;120:108701. doi: 10.1016/j.ejrad.2019.108701. Epub 2019 Oct 4.
3
Node positive breast cancer: Concordance between baseline PET/CT and sentinel node assessment after neoadjuvant therapy.阳性淋巴结乳腺癌：新辅助治疗前后基线 PET/CT 与前哨淋巴结评估的一致性。
Surg Oncol. 2019 Sep;30:1-5. doi: 10.1016/j.suronc.2019.05.006. Epub 2019 May 18.
4
Sentinel Node Lymph Node Surgery After Neoadjuvant Therapy: Principles and Techniques.新辅助治疗后前哨淋巴结手术：原则与技术。
Ann Surg Oncol. 2019 Oct;26(10):3040-3045. doi: 10.1245/s10434-019-07591-6. Epub 2019 Jul 24.
5
The volumetric-tumour histogram-based analysis of intravoxel incoherent motion and non-Gaussian diffusion MRI: association with prognostic factors in HER2-positive breast cancer.基于体素内不相干运动和非高斯扩散 MRI 的容积直方图分析：与 HER2 阳性乳腺癌预后因素的相关性。
J Transl Med. 2019 Jul 2;17(1):182. doi: 10.1186/s12967-019-1911-6.
6
Comparison of Pathologic Response Evaluation Systems After Neoadjuvant Chemotherapy in Breast Cancers: Correlation With Computer-Aided Diagnosis of MRI Features.新辅助化疗后乳腺癌病理反应评估系统的比较：与 MRI 特征的计算机辅助诊断的相关性。
AJR Am J Roentgenol. 2019 Oct;213(4):944-952. doi: 10.2214/AJR.18.21016. Epub 2019 Jun 25.
7
Comparison of MRI and US in Tumor Size Evaluation of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy.MRI与超声在接受新辅助化疗的乳腺癌患者肿瘤大小评估中的比较。
Eur J Breast Health. 2019 Apr 1;15(2):119-124. doi: 10.5152/ejbh.2019.4547. eCollection 2019 Apr.
8
Monitoring breast cancer response to neoadjuvant chemotherapy with ultrasound signal statistics and integrated backscatter.用超声信号统计和背向散射积分监测新辅助化疗的乳腺癌反应。
PLoS One. 2019 Mar 14;14(3):e0213749. doi: 10.1371/journal.pone.0213749. eCollection 2019.
9
Early PET response predicts complete response.早期PET反应可预测完全缓解。
Nat Rev Clin Oncol. 2019 Apr;16(4):208. doi: 10.1038/s41571-019-0189-1.
10
Comparison of mammography, digital breast tomosynthesis, automated breast ultrasound, magnetic resonance imaging in evaluation of residual tumor after neoadjuvant chemotherapy.比较新辅助化疗后残余肿瘤评估中的乳腺 X 线摄影、数字乳腺断层合成、自动乳腺超声、磁共振成像。
Eur J Radiol. 2018 Nov;108:261-268. doi: 10.1016/j.ejrad.2018.09.032. Epub 2018 Oct 2.
Zotero 插件